Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CVHNLC

Next Previous
Drug Profile

CVHNLC

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CureVac
  • Developer CureVac; myNEO
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Squamous cell cancer

Most Recent Events

  • 07 Apr 2025 Preclinical trials in Squamous cell cancer in Germany (Parenteral), prior to April 2025 (CureVac pipeline, April 2025)
  • 07 Apr 2025 US FDA approves IND application for CVHNLC in Squamous cell cancer
  • 07 Apr 2025 CureVac plans a phase I trial for Squamous cell cancer (Combination therapy, Late stage disease, Metastatic disease) in the second half of 2025 (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top